News
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the companyās new HIV prevention drug, Yeztugo, to ...
Industries to Neutral from Buy after the building materials company reported weaker quarterly earnings and lowered its guidance on North America, its largest market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results